Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash & Equivalents (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash & Equivalents for 4 consecutive years, with $48.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 26.2% to $48.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.9 million, a 26.2% increase, with the full-year FY2025 number at $48.9 million, up 26.2% from a year prior.
  • Cash & Equivalents was $48.9 million for Q4 2025 at Spruce Biosciences, up from $10.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $98.8 million in Q3 2023 to a low of $10.7 million in Q3 2025.
  • A 4-year average of $52.2 million and a median of $48.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 356.38% in 2023, then plummeted 82.23% in 2025.
  • Spruce Biosciences' Cash & Equivalents stood at $24.5 million in 2022, then surged by 293.43% to $96.3 million in 2023, then tumbled by 59.77% to $38.8 million in 2024, then increased by 26.2% to $48.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Cash & Equivalents are $48.9 million (Q4 2025), $10.7 million (Q3 2025), and $16.4 million (Q2 2025).